Your browser doesn't support javascript.
loading
Identification and characterization of novel genetic variants in the first Chinese family of mucopolysaccharidosis IIIC (Sanfilippo C syndrome).
Zhao, Hongjun; Wang, Lijing; Zhang, Mengfei; Wang, Huakun; Zhang, Sizhe; Wu, Junjiao; Tang, Yu.
Affiliation
  • Zhao H; Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
  • Wang L; Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Xiangya Hospital, Central South University, Changsha, China.
  • Zhang M; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Wang H; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Zhang S; Department of Geriatrics, Aging Research Center, Xiangya Hospital, Central South University, Changsha, China.
  • Wu J; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Tang Y; Department of Geriatrics, Aging Research Center, Xiangya Hospital, Central South University, Changsha, China.
J Cell Mol Med ; 28(8): e18307, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38613342
ABSTRACT
Mucopolysaccharidosis type IIIC (MPS IIIC) is one of inherited lysosomal storage disorders, caused by deficiencies in lysosomal hydrolases degrading acidic mucopolysaccharides. The gene responsible for MPS IIIC is HGSNAT, which encodes an enzyme that catalyses the acetylation of the terminal glucosamine residues of heparan sulfate. So far, few studies have focused on the genetic landscape of MPS IIIC in China, where IIIA and IIIB were the major subtypes. In this study, we utilized whole-exome sequencing (WES) to identify novel compound heterozygous variants in the HGSNAT gene from a Chinese patient with typical MPS IIIC symptoms c.743G>A; p.Gly248Glu and c.1030C>T; p.Arg344Cys. We performed in silico analysis and experimental validation, which confirmed the deleterious pathogenic nature of both variants, as evidenced by the loss of HGSNAT activity and failure of lysosomal localization. To the best of our knowledge, the MPS IIIC is first confirmed by clinical, biochemical and molecular genetic findings in China. Our study thus expands the spectrum of MPS IIIC pathogenic variants, which is of importance to dissect the pathogenesis and to carry out clinical diagnosis of MPS IIIC. Moreover, this study helps to depict the natural history of Chinese MPS IIIC populations.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidoses / Mucopolysaccharidosis III Limits: Humans Country/Region as subject: Asia Language: En Journal: J Cell Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country: China Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mucopolysaccharidoses / Mucopolysaccharidosis III Limits: Humans Country/Region as subject: Asia Language: En Journal: J Cell Mol Med Journal subject: BIOLOGIA MOLECULAR Year: 2024 Document type: Article Affiliation country: China Country of publication: Reino Unido